118 related articles for article (PubMed ID: 37757592)
1. Carboplatin dosage: prospective evaluation of a simple formula based on renal function.
Calvert AH; Newell DR; Gumbrell LA; O'Reilly S; Burnell M; Boxall FE; Siddik ZH; Judson IR; Gore ME; Wiltshaw E
J Clin Oncol; 2023 Oct; 41(28):4453-4454. PubMed ID: 37757592
[TBL] [Abstract][Full Text] [Related]
2. Carboplatin dosage: prospective evaluation of a simple formula based on renal function.
Calvert AH; Newell DR; Gumbrell LA; O'Reilly S; Burnell M; Boxall FE; Siddik ZH; Judson IR; Gore ME; Wiltshaw E
J Clin Oncol; 1989 Nov; 7(11):1748-56. PubMed ID: 2681557
[TBL] [Abstract][Full Text] [Related]
3. The use of the Calvert formula to determine the optimal carboplatin dosage.
van Warmerdam LJ; Rodenhuis S; ten Bokkel Huinink WW; Maes RA; Beijnen JH
J Cancer Res Clin Oncol; 1995; 121(8):478-86. PubMed ID: 7642691
[TBL] [Abstract][Full Text] [Related]
4. Carboplatin and etoposide pharmacokinetics in patients with testicular teratoma.
Newell DR; Eeles RA; Gumbrell LA; Boxall FE; Horwich A; Calvert AH
Cancer Chemother Pharmacol; 1989; 23(6):367-72. PubMed ID: 2469544
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of carboplatin administered with lobradimil to pediatric patients with brain tumors.
Warren K; Gervais A; Aikin A; Egorin M; Balis FM
Cancer Chemother Pharmacol; 2004 Sep; 54(3):206-12. PubMed ID: 15156345
[TBL] [Abstract][Full Text] [Related]
6. Carboplatin pharmacokinetics in children: the development of a pediatric dosing formula. The United Kingdom Children's Cancer Study Group.
Newell DR; Pearson AD; Balmanno K; Price L; Wyllie RA; Keir M; Calvert AH; Lewis IJ; Pinkerton CR; Stevens MC
J Clin Oncol; 1993 Dec; 11(12):2314-23. PubMed ID: 8246021
[TBL] [Abstract][Full Text] [Related]
7. Prediction of carboplatin clearance calculated by patient characteristics or 24-hour creatinine clearance: a comparison of the performance of three formulae.
Okamoto H; Nagatomo A; Kunitoh H; Kunikane H; Watanabe K
Cancer Chemother Pharmacol; 1998; 42(4):307-12. PubMed ID: 9744776
[TBL] [Abstract][Full Text] [Related]
8. Analysis of carboplatin dosing in patients with a glomerular filtration rate greater than 125 mL/min: To cap or not to cap? A retrospective analysis and review.
Morrow A; Garland C; Yang F; De Luna M; Herrington JD
J Oncol Pharm Pract; 2019 Oct; 25(7):1651-1657. PubMed ID: 30336729
[TBL] [Abstract][Full Text] [Related]
9. Extension of the Calvert formula to patients with severe renal insufficiency.
Oguri T; Shimokata T; Ito I; Yasuda Y; Sassa N; Nishiyama M; Hamada A; Hasegawa Y; Ando Y
Cancer Chemother Pharmacol; 2015 Jul; 76(1):53-9. PubMed ID: 25957958
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetics of carboplatin, etoposide and melphalan in children: a re-evaluation of paediatric dosing formulas for carboplatin in patients with normal or mild impairment of renal function.
Duong JK; Veal GJ; Nath CE; Shaw PJ; Errington J; Ladenstein R; Boddy AV
Br J Clin Pharmacol; 2019 Jan; 85(1):136-146. PubMed ID: 30261554
[TBL] [Abstract][Full Text] [Related]
11. Measured versus estimated glomerular filtration rate in the Calvert equation: influence on carboplatin dosing.
Donahue A; McCune JS; Faucette S; Gillenwater HH; Kowalski RJ; Socinski MA; Lindley C
Cancer Chemother Pharmacol; 2001 May; 47(5):373-9. PubMed ID: 11391850
[TBL] [Abstract][Full Text] [Related]
12. Carboplatin dosing based on measurement of renal function--experience at the Peter MacCallum Cancer Institute.
Millward MJ; Webster LK; Toner GC; Bishop JF; Rischin D; Stokes KH; Johnston VK; Hicks R
Aust N Z J Med; 1996 Jun; 26(3):372-9. PubMed ID: 8811211
[TBL] [Abstract][Full Text] [Related]
13. Carboplatin dosage formulae can generate inaccurate predictions of Carboplatin exposure in carboplatin/paclitaxel combination regimens.
Nannan Panday VR; van Warmerdam LJ; Huizing MT; Ten Bokkel Huinink WW; Vermorken JB; Giaccone G; Veenhof CH; Schellens JH; Beijnen JH
Clin Drug Investig; 1998; 15(4):327-35. PubMed ID: 18370488
[TBL] [Abstract][Full Text] [Related]
14. Prospective evaluation of pharmacokinetically guided dosing of carboplatin in Japanese patients with cancer.
Shimokata T; Ando Y; Yasuda Y; Hamada A; Kawada K; Saito H; Matsuo S; Kondo M; Imaizumi K; Hasegawa Y
Cancer Sci; 2010 Dec; 101(12):2601-5. PubMed ID: 20860621
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and pharmacodynamics of carboplatin administered in a high-dose combination regimen with thiotepa, cyclophosphamide and peripheral stem cell support.
van Warmerdam LJ; Rodenhuis S; van der Wall E; Maes RA; Beijnen JH
Br J Cancer; 1996 Apr; 73(8):979-84. PubMed ID: 8611435
[TBL] [Abstract][Full Text] [Related]
16. Phase I evaluation of carboplatin by use of a dosing strategy based on a targeted area under the platinum concentration-versus-time curve and individual glomerular filtration rate in cats with tumors.
Bailey DB; Rassnick KM; Dykes NL; Pendyala L
Am J Vet Res; 2009 Jun; 70(6):770-6. PubMed ID: 19496668
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of Calvert's formula for dosage adjustment of carboplatin in Japanese patients with hormone refractory prostate cancer.
Sato E; Yano I; Jiko M; Takahashi K; Motohashi H; Masuda S; Katsura T; Nishiyama H; Segawa T; Ito N; Kamoto T; Ogawa O; Inui K
Biol Pharm Bull; 2006 Jul; 29(7):1441-4. PubMed ID: 16819185
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of serum iohexol clearance for use in predicting carboplatin clearance in cats.
Bailey DB; Rassnick KM; Prey JD; Dykes NL
Am J Vet Res; 2009 Sep; 70(9):1135-40. PubMed ID: 19719430
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetically guided dose escalation of carboplatin in epithelial ovarian cancer: effect on drug-plasma AUC and peripheral blood drug-DNA adduct levels.
Ghazal-Aswad S; Tilby MJ; Lind M; Baily N; Sinha DP; Calvert AH; Newell DR
Ann Oncol; 1999 Mar; 10(3):329-34. PubMed ID: 10355578
[TBL] [Abstract][Full Text] [Related]
20. Effect of glomerular filtration rate on clearance and myelotoxicity of carboplatin in cats with tumors.
Bailey DB; Rassnick KM; Erb HN; Dykes NL; Hoopes PJ; Page RL
Am J Vet Res; 2004 Nov; 65(11):1502-7. PubMed ID: 15566088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
